** U.S. listed-shares of Merus NV MRUS.O up about 3% at $46.19 premarket
** Co has entered into a U.S. commercialization agreement with private biotech Partner Therapeutics
** Under the deal, Partner will assume full rights to U.S. commercialization of MRUS' gene-targeting cancer therapy zenocutuzumab or zeno for the treatment of NRG1 fusion-positive cancer in the United States
** In exchange, MRUS will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments tied to the therapy's future annual sales
** Last month, U.S. Food and Drug Administration extended the review of zeno to allow sufficient time to assess some recent information submitted by MRUS to the agency
** Co is seeking approval for zeno, which targets the NRG1 gene associated with progression of several tumors, for treatment of hard-to-treat types of lung and pancreatic cancers
** As of last close, MRUS was up ~57% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。